PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-63.84%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-88.24%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-87.91%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-87.91%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-63.84%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-63.84%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
53.61%
OCF/share CAGR of 53.61% while AVXL is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
53.61%
OCF/share CAGR of 53.61% while AVXL is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
53.61%
3Y OCF/share CAGR of 53.61% while AVXL is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
35.25%
Positive 10Y CAGR while AVXL is negative. John Neff might see a substantial advantage in bottom-line trajectory.
35.25%
Positive 5Y CAGR while AVXL is negative. John Neff might view this as a strong mid-term relative advantage.
35.25%
Positive short-term CAGR while AVXL is negative. John Neff would see a clear advantage in near-term profit trajectory.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1280.26%
Positive asset growth while AVXL is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-28.60%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
50.95%
Debt shrinking faster vs. AVXL's 221.18%. David Dodd sees a safer balance sheet if it doesn't impair future growth.
No Data
No Data available this quarter, please select a different quarter.
47.25%
SG&A growth well above AVXL's 49.38%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.